Targeting HER2-positive breast cancer: advances and future directions. [Review] (Record no. 10972)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02117nam a22003737a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 221213s20222022 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1474-1776 |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1038/s41573-022-00579-0 [doi] |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1038/s41573-022-00579-0 [pii] |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | PMC9640784 [pmc] |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
PMID | 36344672 |
245 ## - TITLE STATEMENT | |
Title | Targeting HER2-positive breast cancer: advances and future directions. [Review] |
251 ## - Source | |
Source | Nature Reviews. Drug Discovery. 2022 Nov 07 |
252 ## - Abbreviated Source | |
Abbreviated source | Nat Rev Drug Discov. 2022 Nov 07 |
253 ## - Journal Name | |
Journal name | Nature reviews. Drug discovery |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Year | 2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Manufacturer | FY2023 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Publication date | 2022 Nov 07 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Publication status | aheadofprint |
266 ## - Date added to catalog | |
Date added to catalog | 2022-12-13 |
520 ## - SUMMARY, ETC. | |
Abstract | The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug - the monoclonal antibody trastuzumab - almost 25 years ago. Since then, progress has been swift and the impressive clinical activity across multiple trials with monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates that target HER2 has spawned extensive efforts to develop newer platforms and more targeted therapies. This Review discusses the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system. Copyright © 2022. Springer Nature Limited. |
546 ## - LANGUAGE NOTE | |
Language note | English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
656 ## - INDEX TERM--OCCUPATION | |
Department | Associate Dean for Research Development |
656 ## - INDEX TERM--OCCUPATION | |
Department | MedStar Health |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Journal Article |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Review |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Swain, Sandra M |
Institution Code | MSH |
790 ## - Authors | |
All authors | Hamilton E, Shastry M, Swain SM |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
DOI | <a href="https://dx.doi.org/10.1038/s41573-022-00579-0">https://dx.doi.org/10.1038/s41573-022-00579-0</a> |
Public note | https://dx.doi.org/10.1038/s41573-022-00579-0 |
858 ## - ORCID | |
ORCID text | Swain, Sandra M |
Orcid | <a href="http://orcid.org/0000-0002-1320-3830">http://orcid.org/0000-0002-1320-3830</a> |
Name | http://orcid.org/0000-0002-1320-3830 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Journal Article |
Item type description | Article |
Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MedStar Authors Catalog | MedStar Authors Catalog | 12/13/2022 | 36344672 | 36344672 | 12/13/2022 | 12/13/2022 | Journal Article |